BRPI0711221A2 - Composto, composição farmcêutica, método para o tratamento, prevenção ou melhora de um ou mais sintomas de doença mediada por receptor adrenérgico beta, método para tratar, prevenir ou melhorar um o mais sintomas de uma doença selecionada do grupo consistindo em uma desordem de ansiedade social, uma desordem de ansiedade, hipertirodismo, tremor, glaucoma, hipertensão, enxerto de desvio de artéria coronária, angina estável crônica, arritmia atrial , enxaqueca , varizes, esofagicas sangrando, estenose subaórtica hipertrófica, ataque cardíaco , infarto pós miocárdio, função ventricular esquerda diminuída após infarto do miocárdio recente e qualquer desordem melhorada por modulares do receptor adrenérgico beta e metodo para modular atividade de receptor adrenérgico beta - Google Patents

Composto, composição farmcêutica, método para o tratamento, prevenção ou melhora de um ou mais sintomas de doença mediada por receptor adrenérgico beta, método para tratar, prevenir ou melhorar um o mais sintomas de uma doença selecionada do grupo consistindo em uma desordem de ansiedade social, uma desordem de ansiedade, hipertirodismo, tremor, glaucoma, hipertensão, enxerto de desvio de artéria coronária, angina estável crônica, arritmia atrial , enxaqueca , varizes, esofagicas sangrando, estenose subaórtica hipertrófica, ataque cardíaco , infarto pós miocárdio, função ventricular esquerda diminuída após infarto do miocárdio recente e qualquer desordem melhorada por modulares do receptor adrenérgico beta e metodo para modular atividade de receptor adrenérgico beta Download PDF

Info

Publication number
BRPI0711221A2
BRPI0711221A2 BRPI0711221-1A BRPI0711221A BRPI0711221A2 BR PI0711221 A2 BRPI0711221 A2 BR PI0711221A2 BR PI0711221 A BRPI0711221 A BR PI0711221A BR PI0711221 A2 BRPI0711221 A2 BR PI0711221A2
Authority
BR
Brazil
Prior art keywords
adrenergic receptor
beta adrenergic
sterating
disorder
symptoms
Prior art date
Application number
BRPI0711221-1A
Other languages
English (en)
Inventor
G. Gant Thomas
Sarshar Sepehr
Original Assignee
Auspex Pharmaceuticals, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals, Inc filed Critical Auspex Pharmaceuticals, Inc
Publication of BRPI0711221A2 publication Critical patent/BRPI0711221A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSTO, COMPOSIçãO FARMACêUTICA, MéTODO PARA O TRATAMENTO, PREVENçãO OU MELHORA DE UM OU MAIS SINTOMAS DE UMA DOENçA MEDIADA POR RECEPTOR ADRENéRGICO BETA, MéTODO PARA TRATAR, PREVENIR OU MELHORAR UM OU MAIS SINTOMAS DE UMA DOENçA SELECIONADA DO GRUPO CONSISTINDO EM UMA DESORDEM DE ANSIEDADE SOCIAL, UMA DESORDEM DE ANSIEDADE, HIPERTIROIDISMO, TREMOR, GLAUCOMA, HIPERTENSãO, ENXERTO DE DESVIO DE ARTéRIACORONARIA, ANGINA ESTáVEL CRÈNICA, ARRITMIA ATRIAL, ENXAQUECA, VARIZES ESOFáGICAS SANGRANDO, ESTENOSE SUBAóRTICA HIPERTRóFICA, ATAQUE CARDìACO, INFARTO PóS MIOCáRDIO, FUNçãO VENTRICULAR ESQUERDA DIMINUìDA APóS INFARTO DO MIOCáRDIO RECENTE E QUALQUER DESORDEM MELHORADA POR MODULADORES DO RECEPTOR ADRENéRGICO BETA E MéTODO PARA MODULAR ATIVIDADE DE RECEPTOR ADRENéRGICO BETA. Apresentados aqui estão compostos substituidos de aminoglicidil da Fórmula (1), processos de preparação e composições farmacêuticas dos mesmos e métodos de seu uso para tratar, prevenir ou melhorar um ou vários sintomas de uma desordem de ansiedade social, uma desordem de ansiedade, hipertireoidismo, tremor, glaucoma, hipertensão, enxerto de desvio de artéria coronária, angina estável crónica, arritmia atrial, enxaqueca, varizes esofágicas sangrando, estenose subaórtica hipertrófica, parada cardíaca, infarto pós-miocardio, função ventricular esquerda diminuída após infarto de miocárdico recente, e/ou qualquer desordem melhorada por moduladores de receptor adrenérgico beta.
BRPI0711221-1A 2006-05-26 2007-05-25 Composto, composição farmcêutica, método para o tratamento, prevenção ou melhora de um ou mais sintomas de doença mediada por receptor adrenérgico beta, método para tratar, prevenir ou melhorar um o mais sintomas de uma doença selecionada do grupo consistindo em uma desordem de ansiedade social, uma desordem de ansiedade, hipertirodismo, tremor, glaucoma, hipertensão, enxerto de desvio de artéria coronária, angina estável crônica, arritmia atrial , enxaqueca , varizes, esofagicas sangrando, estenose subaórtica hipertrófica, ataque cardíaco , infarto pós miocárdio, função ventricular esquerda diminuída após infarto do miocárdio recente e qualquer desordem melhorada por modulares do receptor adrenérgico beta e metodo para modular atividade de receptor adrenérgico beta BRPI0711221A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US80877106P 2006-05-26 2006-05-26
US60/808,771 2006-05-26
US84020606P 2006-08-25 2006-08-25
US60/840,206 2006-08-25
PCT/US2007/012466 WO2007139923A1 (en) 2006-05-26 2007-05-25 Deuterated aminoglycidyl compounds

Publications (1)

Publication Number Publication Date
BRPI0711221A2 true BRPI0711221A2 (pt) 2012-03-13

Family

ID=38515472

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711221-1A BRPI0711221A2 (pt) 2006-05-26 2007-05-25 Composto, composição farmcêutica, método para o tratamento, prevenção ou melhora de um ou mais sintomas de doença mediada por receptor adrenérgico beta, método para tratar, prevenir ou melhorar um o mais sintomas de uma doença selecionada do grupo consistindo em uma desordem de ansiedade social, uma desordem de ansiedade, hipertirodismo, tremor, glaucoma, hipertensão, enxerto de desvio de artéria coronária, angina estável crônica, arritmia atrial , enxaqueca , varizes, esofagicas sangrando, estenose subaórtica hipertrófica, ataque cardíaco , infarto pós miocárdio, função ventricular esquerda diminuída após infarto do miocárdio recente e qualquer desordem melhorada por modulares do receptor adrenérgico beta e metodo para modular atividade de receptor adrenérgico beta

Country Status (7)

Country Link
US (1) US20090182057A1 (pt)
EP (1) EP2032525A1 (pt)
JP (1) JP2009538355A (pt)
AU (1) AU2007267912A1 (pt)
BR (1) BRPI0711221A2 (pt)
CA (1) CA2653209A1 (pt)
WO (1) WO2007139923A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100076087A1 (en) * 2005-10-06 2010-03-25 Auspex Pharmaceuticals, Inc. Methods of reduction of interpatient variability
CN102149280B (zh) 2008-07-15 2017-05-24 泰拉科斯有限公司 氘化苄基苯衍生物及其使用方法
CA2740952C (en) * 2008-10-22 2015-12-29 Ian L. Scott Compounds for treating ophthalmic diseases and disorders
MA41557A (fr) * 2015-02-18 2017-12-26 Auspex Pharmaceuticals Inc Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2
CN108339415A (zh) * 2018-01-25 2018-07-31 合肥中科富华新材料有限公司 一种血浆分离膜及其制备方法
CN111039887A (zh) * 2018-10-12 2020-04-21 上海安谱实验科技股份有限公司 一种稳定同位素标记的呋喃它酮代谢物及其合成方法
WO2026019925A1 (en) * 2024-07-16 2026-01-22 University Of Florida Research Foundation, Incorporated Beta-adrenergic receptor antagonists from kava

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
DE10125967C1 (de) * 2001-05-29 2002-07-11 Infineon Technologies Ag DRAM-Zellanordnung mit vertikalen MOS-Transistoren und Verfahren zu deren Herstellung
US6500454B1 (en) * 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives

Also Published As

Publication number Publication date
CA2653209A1 (en) 2007-12-06
US20090182057A1 (en) 2009-07-16
EP2032525A1 (en) 2009-03-11
WO2007139923A1 (en) 2007-12-06
JP2009538355A (ja) 2009-11-05
AU2007267912A1 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
BRPI0711221A2 (pt) Composto, composição farmcêutica, método para o tratamento, prevenção ou melhora de um ou mais sintomas de doença mediada por receptor adrenérgico beta, método para tratar, prevenir ou melhorar um o mais sintomas de uma doença selecionada do grupo consistindo em uma desordem de ansiedade social, uma desordem de ansiedade, hipertirodismo, tremor, glaucoma, hipertensão, enxerto de desvio de artéria coronária, angina estável crônica, arritmia atrial , enxaqueca , varizes, esofagicas sangrando, estenose subaórtica hipertrófica, ataque cardíaco , infarto pós miocárdio, função ventricular esquerda diminuída após infarto do miocárdio recente e qualquer desordem melhorada por modulares do receptor adrenérgico beta e metodo para modular atividade de receptor adrenérgico beta
JP2009114205A5 (pt)
Sakamoto et al. Landiolol, an Ultra-Short-Acting β1-Blocker, More Effectively Terminates Atrial Fibrillation Than Diltiazem After Open Heart Surgery–Prospective, Multicenter, Randomized, Open-Label Study (JL-KNIGHT Study)–
BRPI0517567A (pt) composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo, composição farmacêutica, usos de um composto ou um sal, solvato, ou derivado fisiologicamente funcional farmaceuticamente aceitável do mesmo e de uma composição farmacêutica, e, processo para preparar um composto
JP2019206562A5 (pt)
CN110139643A (zh) 一种用于治疗代谢紊乱综合征、炎症及其并发症的药物成分
EP1948178A2 (en) Methods of treating atrial fibrillation with p38 inhibitor compounds
Bunch et al. Revisiting rate versus rhythm control in atrial fibrillation—timing matters
Li et al. Mitochondria and the pathophysiological mechanism of atrial fibrillation
WO2022089614A1 (zh) 胸苷衍生物在制备药物中的应用
CN102001971B (zh) N-(4-胍基丁基)丁香酰胺衍生物及其医药用途
Toso et al. Does antiarrhythmic drugs premedication improve electrical cardioversion success in persistent atrial fibrillation?
CN100418532C (zh) 治疗多种疾病的NF-κB化合物抑制剂
Choudhury et al. Antiarrhythmic drugs in atrial fibrillation: an overview of new agents, their mechanisms of action and potential clinical utility
Hafez et al. Carvedilol: New pharmacological approaches
EP2862573B1 (en) Composition for treating or preventing diseases caused by vascular permeability, containing imatinib or pharmaceutically acceptable salt thereof as active ingredient
Izhar et al. When should we discontinue antiarrhythmic therapy for atrial fibrillation after coronary artery bypass grafting? A prospective randomized study
Fedacko et al. Coenzyme Q10 in heart and brain diseases
JP2010529052A5 (pt)
RU2526466C1 (ru) Средство для стимуляции васкуляризации сердечной мышцы при постинфарктном ее ремоделировании в эксперименте
CN110025617A (zh) 双去甲基汉防己甲素双甲酸乙酯与酪氨酸激酶抑制剂的药物组合物
Font et al. PAR 1 contribution in acute electrophysiological properties of oral anticoagulants in rabbit pulmonary vein sleeve preparations
JP2008505127A (ja) ニコチン酸誘導体或いはフィブリン酸誘導体を用いた併用療法
JP7137852B2 (ja) ９‐β‐Ｄ‐アラビノフラノシルヒポキサンチンによる不整脈治療
WO2015025816A1 (ja) キマーゼ阻害剤およびキマーゼ阻害剤を含有する薬剤

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 4A E 5A ANUIDADES.